Cooley-Led Biopharm Startup Plans For $60M IPO
AN2 Therapeutics, a biopharmaceutical startup developing treatment for a rare form of lung disease, set a price range on Monday for an initial public offering that would raise $60 million at...To view the full article, register now.
Already a subscriber? Click here to view full article